Enzalutamide-resistant LNCaP ARF877L Mutation KI model
We have established an enzalutamide-resistant (LNCaP AR-F877L mutation) KI prostate cancer model to support the development of next-generation therapeutics. An LNCaP AR-F877L KI cell line was shown to be resistant to enzalutamide, and in vivo animal validation studies demonstrated that enzalutamide was not efficacious to prevent tumor growth using this drug-resistant model.
Check out our comprehensive platform of drug-resistant animal models
Enzalutamide-resistant LNCAP AR F877L mutant KI model
Related Content
Unlike conventional protein-targeted therapies, which often provide only transient effects, nucleic acid therapeutics have the potential for long-lasting effects and...
VIEW RESOURCETargeted protein degradation (TPD) approaches, including molecular glue degraders (MGDs) and proteolysis targeting chimeras (PROTACs), can overcome traditional occupancy-based inhibitor...
VIEW RESOURCE